Outcome of Subsequent Therapies After (177)Lu-Vipivotide Tetraxetan for Metastatic Castrate-Resistant Prostate Cancer: A Tertiary Cancer Center Experience

Uro-Oncology

Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer

Prostate Cancer Prostatic Dis

George DJ, Ramaswamy K, Yang H, Liu Q, Zhang A, Greatsinger A, Ivanova J, Thompson B, Emir B, Hong A, Freedland SJ

doi: 10.1038/s41391-024-00816-0

Uro-Oncology

Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study

Eur Urol

Saad F, Hussain MHA, Tombal B, Fizazi K, Sternberg CN, Crawford ED, Nordquist LT, Bögemann M, Tutrone R, Shore ND, Belkoff L, Fralich T, Jhaveri J, Srinivasan S, Li R, Verholen F, Kuss I, Smith MR

doi: 10.1016/j.eururo.2024.03.036

Uro-Oncology

Bellmunt risk score as a survival predictor in patients with metastatic castration-resistant prostate cancer

Prostate

Büttner T, Klümper N, Weiten R, Lossin P, Latz S, Jacobs C, Ritter M, Hauser S, Ellinger J, Krausewitz P

doi: 10.1002/pros.24747

Uro-Oncology

Efficacy and Feasibility of Cabazitaxel for Very Elderly Patients of ≥ 80 Years of Age With Metastatic Castration-Resistant Prostate Cancer: A Real-World Multi-Intuitional Analysis

Prostate

Suzuki K, Hirata J, Okamura Y, Bando Y, Hara T, Terakawa T, Hyodo Y, Chiba K, Teishima J, Miyake H

doi: 10.1002/pros.24889

Uro-Oncology

Treatment patterns and oncological outcomes of older adults with metastatic prostate cancer in real-world setting

J Am Geriatr Soc

Wenzel M, Hoeh B, Wagner N, Koll F, Siech C, Humke C, Steuber T, Graefen M, Tilki D, Kluth L, Traumann M, Banek S, Chun FKH, Mandel P

doi: 10.1111/jgs.19045

Further Publications Urology

Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trials

Prostate Cancer Prostatic Dis

Shelan M, Achard V, Appiagyei F, Mose L, Zilli T, Fankhauser CD, Zamboglou C, Mohamad O, Aebersold DM, Cathomas R

doi: 10.1038/s41391-024-00829-9

Uro-Oncology

Prostate Radiotherapy in Low-volume Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis

Eur Urol

Roy S, Fervaha G, Spratt DE, Sun Y, Kishan AU, Loblaw A, Malone S, Ong M, Saad F, Wallis CJD, Morgan SC

doi: 10.1016/j.eururo.2024.03.018

Uro-Oncology

The detection rate for prostate cancer in systematic and targeted prostate biopsy in biopsy-naive patients, according to the localization of the lesion at the mpMRI: A single-center retrospective observational study

Prostate

Massanova M, Barone B, Caputo VF, Napolitano L, Ponsiglione A, Del Giudice F, Ferro M, Lucarelli G, Lasorsa F, Busetto GM, Robertson S, Trama F, Imbimbo C, Crocetto F

doi: 10.1002/pros.24761

Uro-Oncology

Impact of Intraoperative Opioid Use and a Combined Anesthesia Regimen in Patients Undergoing Radical Prostatectomy for Prostate Cancer in a Single-Center Cohort

J Clin Med

Marcon J, Bischoff R, Rattenhuber K, Chaloupka M, Askari D, Jokisch JF, Becker AJ, Pfitzinger PL, Keller P, Berg E, Stief CG, Siegl D, Kowalski C, Buchner A, Pyrgidis N, Weinhold P

doi: 10.3390/jcm13247506

Related content

Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer

Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study

Bellmunt risk score as a survival predictor in patients with metastatic castration-resistant prostate cancer

Efficacy and Feasibility of Cabazitaxel for Very Elderly Patients of ≥ 80 Years of Age With Metastatic Castration-Resistant Prostate Cancer: A Real-World Multi-Intuitional Analysis

Treatment patterns and oncological outcomes of older adults with metastatic prostate cancer in real-world setting

Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trials

Prostate Radiotherapy in Low-volume Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis

The detection rate for prostate cancer in systematic and targeted prostate biopsy in biopsy-naive patients, according to the localization of the lesion at the mpMRI: A single-center retrospective observational study

Impact of Intraoperative Opioid Use and a Combined Anesthesia Regimen in Patients Undergoing Radical Prostatectomy for Prostate Cancer in a Single-Center Cohort